Litcius/Paper detail

Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

Noa Eliakim‐Raz, Amir Massarweh, Amos Stemmer, Salomon M. Stemmer

2021JAMA Oncology56 citationsDOIOpen Access PDF

Abstract

This cohort study examines the durability of immune response from BNT162b2 vaccination for severe acute respiratory syndrome coronavirus 2 in patients with cancer vs healthy controls.

Topics & Concepts

MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VaccinationCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakMEDLINEVirologyInternal medicineOutbreakInfectious disease (medical specialty)LawDiseasePolitical scienceSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesVaccine Coverage and Hesitancy